# A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

> **NCT05044234** · PHASE2 · TERMINATED · sponsor: **AbbVie** · enrollment: 156 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Cedirogant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05044234
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-16
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 156 (ACTUAL)
- **Why stopped:** Company Decision
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05044234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05044234, "A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05044234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*